Explore

Rapid Read Rapid Read
Insilico Medicine's Rentosertib Shows Potential for Biological Age Reversal in IPF Trial

Insilico Medicine's Rentosertib Shows Potential for Biological Age Reversal in IPF Trial

A new study published in Nature Biotechnology indicates that rentosertib, an AI-designed drug for idiopathic pulmonary fibrosis (IPF), may reverse biological aging. Researchers analyzed longitudinal serum samples from 42 participants in a Phase 2a trial of rentosertib, tracking 2,841 proteins. Six independently developed proteomic aging clocks consistently detected a younger biological age signal in patients treated with rentosertib. The most consistent age reduction was observed at week four with the 30 mg twice-daily regimen. Rentosertib, an inhibitor of TNIK (TRAF2- and NCK-interacting kinase), was developed by Insilico Medicine, whose AI platform identified TNIK as a target at the intersection of fibrosis and six hallmarks of aging. This study represents a clinical test of the premise that a drug designed with aging biology in mind can also modify aging itself, even within a conventional disease trial. While the study acknowledges the ambiguity of whether the drug modifies aging directly or simply make...
Rapid Read Rapid Read
Insilico Medicine's AI-Designed Drug, Rentosertib, Shows Potential for Biological Age Reversal in Clinical Trial

Insilico Medicine's AI-Designed Drug, Rentosertib, Shows Potential for Biological Age Reversal in Clinical Trial

Insilico Medicine's AI-generated drug, rentosertib, an inhibitor of TNIK (TRAF2- and NCK-interacting kinase), has shown promising results in a Phase 2a clinical trial for idiopathic pulmonary fibrosis (IPF). The study, published in Nature Biotechnology, analyzed 2,841 proteins in longitudinal serum samples from 42 participants. Six independently developed proteomic aging clocks consistently indicated a reduction in biological age among participants treated with rentosertib. This finding is significant because Insilico Medicine's AI platform identified TNIK as a target relevant to both fibrosis and six recognized hallmarks of aging, integrating aging biology into the drug's development from its inception. While the study is small and short, the consistent signal across multiple aging clocks suggests a potential dual-purpose benefit for the drug, addressing both disease treatment and aging modulation. The most consistent age reduction was observed at week four with the 30 mg twice-daily regimen.
Rapid Read Rapid Read
Insilico Medicine's AI-Generated Drug Candidate Shows Potential for Biological Age Reversal

Insilico Medicine's AI-Generated Drug Candidate Shows Potential for Biological Age Reversal

Insilico Medicine's AI-generated drug candidate, rentosertib, has demonstrated potential in slowing the aging process, according to recent clinical trial results published in Nature Biotechnology. The study indicated that rentosertib decreases predicted biological age across various regimens, with the most significant effects observed in the 30 mg BID group and at week 4. This research suggests that rentosertib's anti-aging effects operate partially independent of its respiratory benefits, as the dose for optimal lung function improvement differed from that producing the strongest age-reversal signal. This cross-model consistency in the study reinforces that rentosertib's impact on aging-related proteomic signals is a robust biological phenomenon, not merely a model-specific artifact. The study also established a comprehensive workflow for applying aging clocks in clinical trials, covering cohort establishment, omics profiling, multi-clock parallel analysis, result cross-validation, and mechanistic interpr...
Rapid Read Rapid Read
DeepMind Releases AlphaGenome Atlas to Map All Possible Human DNA Mutations

DeepMind Releases AlphaGenome Atlas to Map All Possible Human DNA Mutations

DeepMind has launched the AlphaGenome Atlas, a comprehensive dataset providing predictions for all 9 billion possible single-letter changes in the human genome. This petabyte-sized resource is freely available for academic use and aims to guide scientists in deciphering the biological code. The Atlas includes predictions for both coding (2%) and non-coding (98%) regions of DNA, along with a catalog of over 2,500 recurrent DNA motifs. It builds upon DeepMind's previous success with AlphaFold, which predicted protein structures, and is part of a broader initiative to leverage AI for scientific and medical advancements. The Atlas also features an AlphaGenome Variant Impact (AVI) score, a single metric designed to help researchers quickly assess the potential biological effect of a genetic variant. This score has been validated against clinical genomics databases and has aided in prioritizing non-coding variants linked to conditions like severe epilepsy, as demonstrated by a team at the Broad Institute in Camb...
Trendline Trendline
RNAV8 Bio Secures ARPA-H Funding for Programmable RNA Medicines Initiative

RNAV8 Bio Secures ARPA-H Funding for Programmable RNA Medicines Initiative

RNAV8 Bio Secures ARPA-H Funding for Programmable RNA Medicines Initiative
Rapid Read Rapid Read
Capricor Therapeutics Advances DMD Treatment and Vaccine Candidates in Clinical Trials

Capricor Therapeutics Advances DMD Treatment and Vaccine Candidates in Clinical Trials

Capricor Therapeutics, a San Diego-based clinical-stage biotechnology company, is actively developing cell and exosome-based therapeutics for Duchenne Muscular Dystrophy (DMD) and other diseases with significant unmet medical needs in the United States. The company's primary product candidate, Deramiocel, an allogeneic cardiosphere-derived cell therapy, is currently in a Phase 3 clinical trial for DMD treatment. In addition to its DMD focus, Capricor is also engaged in the development of an Exosome protein-based vaccine, which is in preclinical trials for SARS-CoV-2. The company's StealthX Exosome Platform is being utilized for engineered exosomes in vaccine and therapeutic development, with one such candidate already in a Phase 1 clinical study for various therapeutic applications, including targeted RNA, protein, and small molecule therapeutics. Capricor Therapeutics was established in 2005.
Trendline Trendline
U.S. Government Bolsters Domestic Rare Earth Supply Chain with $3.5 Billion in Federal Support

U.S. Government Bolsters Domestic Rare Earth Supply Chain with $3.5 Billion in Federal Support

U.S. Government Bolsters Domestic Rare Earth Supply Chain with $3.5 Billion in Federal Support
Rapid Read Rapid Read
Google DeepMind Releases AI-Powered Atlas for Human DNA Mutation Prediction

Google DeepMind Releases AI-Powered Atlas for Human DNA Mutation Prediction

Google DeepMind has announced the release of AlphaGenome Atlas, an AI-powered database that predicts the biological consequences of all 9 billion possible single-letter changes to human DNA. This comprehensive catalogue is being made freely available to academic researchers worldwide. The AlphaGenome Atlas utilizes an AI model, AlphaGenome, to predict the effects of single-letter genetic mutations across a reference sample of the human genome. It compares each reference base against three possible alternatives, generating approximately 27,000 individual predictions per variant. These predictions cover various aspects, including gene expression and how DNA sequences are transcribed into protein manufacturing instructions, across hundreds of cell and tissue types from humans and mice. The database also includes scores for over 100 million insertions and deletions observed in population databases like the U.K. Biobank and the U.S. National Institutes of Health's 'All of Us' program. DeepMind's vice president ...
Rapid Read Rapid Read
U.S. Lacks Unified Genetic Data Privacy Law, Leading to Fragmented Protections

U.S. Lacks Unified Genetic Data Privacy Law, Leading to Fragmented Protections

The United States currently operates without a general-purpose federal statute specifically addressing genetic data privacy. Instead, the legal landscape is characterized by a fragmented collection of overlapping definitions and regulations tied to various statutory regimes. For instance, the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule defines genetic information as 'protected health information' (PHI) only when held by specific covered entities like health plans or most healthcare providers. This means that genetic data held by direct-to-consumer (DTC) testing companies, such as 23andMe, is generally not considered PHI under HIPAA. The Genetic Information Nondiscrimination Act of 2008 (GINA) offers a broader definition of 'genetic information' but applies strictly to anti-discrimination contexts in employment and group health insurance. State laws further complicate this patchwork, with California's Privacy Rights Act (CPRA) classifying genetic data as 'sensitive personal info...
Rapid Read Rapid Read
AI-Generated Drug Candidate Rentosertib Shows Potential for Anti-Aging and Lung Disease Treatment

AI-Generated Drug Candidate Rentosertib Shows Potential for Anti-Aging and Lung Disease Treatment

An AI-generated drug candidate, rentosertib, developed by Insilico Medicine, has demonstrated potential in slowing aging and treating a chronic lung disease. The drug's molecular structure was created with the assistance of artificial intelligence. Clinical trial results, published in Nature Biotechnology, indicate that rentosertib successfully reduced biological markers associated with aging. While these findings are promising, the drug is still several years away from potential regulatory approval. It is important to note that the anti-aging effects of rentosertib have not yet been tested in healthy patients, with current research focusing on its impact on biological markers rather than direct anti-aging outcomes in a broader population. The development highlights the growing role of AI in drug discovery and its potential to accelerate the identification and creation of novel therapeutic compounds for complex conditions.
Trendline Trendline
AstraZeneca Secures Global Rights for Lung Cancer Drug Zegfrovy, Expanding Oncology Portfolio

AstraZeneca Secures Global Rights for Lung Cancer Drug Zegfrovy, Expanding Oncology Portfolio

AstraZeneca Secures Global Rights for Lung Cancer Drug Zegfrovy, Expanding Oncology Portfolio
Trendline Trendline
Global Microbiome Therapeutics Market Projected to Reach $4.6 Billion by 2035 Amidst Clinical and Regulatory Advancements

Global Microbiome Therapeutics Market Projected to Reach $4.6 Billion by 2035 Amidst Clinical and Regulatory Advancements

Global Microbiome Therapeutics Market Projected to Reach $4.6 Billion by 2035 Amidst Clinical and Regulatory Advancements